ObsEva SA (OBSV) - Financial and Strategic SWOT Analysis Review

December 2021 | 52 pages | ID: O9C583A6514EN
GlobalData

Abstracts

ObsEva SA (OBSV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ObsEva SA (ObsEva) is a clinical-stage biopharmaceutical company that develops and commercializes drugs for women’s reproductive health and pregnancy. The company's product portfolio comprises pipeline products for controlling preterm labor by reducing inflammation, decreasing uterine contractions, and preventing cervical changes and membrane ruptures; for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women and to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation. ObsEva is headquartered in Geneva, Switzerland.

ObsEva SA Key Recent Developments

Nov 22,2021: Obseva Announces Appointment of Stephanie Brown to its Board of Directors
Nov 04,2021: ObsEva Announces Third Quarter 2021 Financial Results and Business Update
Sep 30,2021: ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer
Aug 05,2021: ObsEva Announces Second Quarter 2021 Financial Results and Business Update
May 31,2021: ObsEva Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

ObsEva SA - Key Facts
ObsEva SA - Key Employees
ObsEva SA - Key Employee Biographies
ObsEva SA - Major Products and Services
ObsEva SA - History
ObsEva SA - Company Statement
ObsEva SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
ObsEva SA - Business Description
ObsEva SA - Corporate Strategy
ObsEva SA - SWOT Analysis
SWOT Analysis - Overview
ObsEva SA - Strengths
ObsEva SA - Weaknesses
ObsEva SA - Opportunities
ObsEva SA - Threats
ObsEva SA - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
ObsEva SA, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Nov 22, 2021: Obseva Announces Appointment of Stephanie Brown to its Board of Directors
Nov 04, 2021: ObsEva Announces Third Quarter 2021 Financial Results and Business Update
Sep 30, 2021: ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer
Aug 05, 2021: ObsEva Announces Second Quarter 2021 Financial Results and Business Update
May 31, 2021: ObsEva Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021
May 25, 2021: ObsEva Announces Proposed Changes to the Composition of its Board of Directors
May 06, 2021: ObsEva Announces First Quarter 2021 Financial Results and Business Update
May 06, 2021: ObsEva appoints Clive Bertram as Chief Commercial Officer
Apr 22, 2021: ObsEva Annual General Meeting 2021
Mar 05, 2021: ObsEva Announces Year End 2020 Financial Results and Business Update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

ObsEva SA, Key Facts
ObsEva SA, Key Employees
ObsEva SA, Key Employee Biographies
ObsEva SA, Major Products and Services
ObsEva SA, History
ObsEva SA, Subsidiaries
ObsEva SA, Key Competitors
ObsEva SA, Ratios based on current share price
ObsEva SA, Annual Ratios
ObsEva SA, Annual Ratios (Cont...1)
ObsEva SA, Interim Ratios
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
ObsEva SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

ObsEva SA, Performance Chart (2016 - 2020)
ObsEva SA, Ratio Charts
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
ObsEva SA, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021